In patients with Parkinson’s disease, neurochemical changes seen on molecular imaging could open the door to better treatment of motor dysfunction, new research shows.  Specifically, the decreased expression of protein phosphodiesterase 10A (PDE10A) was seen in patients with Parkinson’s disease on PET scans that used the radioligand carbon 11 IMA107 (¹¹C-IMA107), said investigator Flavia Niccolini, MD, from King’s College London, United Kingdom. {read more here}